Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Summary

Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.

Timeline

Start

2021-04-30

Primary completion

2022-11-30

Completion

2022-11-30

Outcome

Missed primary endpoint

Stopped (Enrollment): “The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame.”

registry analysis (superiority test); Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC vs Placebo; p = 0.68; Fisher Exact NCT04615949 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidiol	Other / unclassified	7.5 mg/kg	Oral

Indications